Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Mitsubishi Tanabe Pharma Corp    4508   JP3469000008

MITSUBISHI TANABE PHARMA CORP

(4508)
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • In view of fundamental criteria, the company is among low performers as far as mid or long-term investment strategy is concerned.
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • This company will be of major interest to investors in search of a high dividend stock.
  • For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
Weaknesses
  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • With an expected P/E ratio at 86.03 and 45.12 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The technical configuration over the long term remains negative on the weekly chart below the resistance level at 1445 JPY
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
MITSUBISHI TANABE PHARMA CO..-19.05%6 489
JOHNSON & JOHNSON0.82%347 446
ROCHE HOLDING LTD.16.27%245 289
MERCK AND COMPANY11.45%218 042
PFIZER-15.95%202 934
NOVARTIS15.60%199 009
NOVO NORDISK AS17.30%124 981
AMGEN1.17%118 105
ASTRAZENECA22.03%117 452
SANOFI10.12%114 785
ABBVIE-21.48%107 027
ELI LILLY AND COMPANY0.38%106 337
GLAXOSMITHKLINE12.10%103 333
BRISTOL-MYERS SQUIBB COMPAN..-2.71%82 721
CELGENE CORPORATION55.05%70 428
BAYER AG10.47%68 980
More Results
Financials (JPY)
Sales 2020 392 B
EBIT 2020 14 017 M
Net income 2020 6 689 M
Finance 2020 341 B
Yield 2020 4,48%
P/E ratio 2020 86,0x
P/E ratio 2021 45,1x
EV / Sales2020 0,92x
EV / Sales2021 0,91x
Capitalization 700 B
Upcoming event on MITSUBISHI TANABE PHARMA C
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation -
Finances -
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes